Please wait while your page loads ...

A Phase 2 Study of CTI-1601 in Adults with Friedreich’s Ataxia

About this research study:

CTI-1601, a drug being developed by Larimar Therapeutics, is intended to increase frataxin levels in people with FA. The goal of this study is to evaluate the safety and tolerability of CTI-1601 injections in people with Friedreich’s ataxia (FA) over 28 days.

Study visits will take place at Clinilabs in Eatontown, NJ. Participation requires about 30 days of overnight stays at Clinilabs and a nearby hotel and several home visits by a nurse. Compensation for time and travel will be provided for qualified participants.

You may be eligible if you:
  • Are 18 years of age or older
  • Have genetically confirmed Friedreich’s ataxia (homozygous GAA repeat expansions)
  • Are able to go the distance of 25 feet with or without an assistive device
  • Are able to transfer from bed to chair either independently or with assistance while still physically contributing to the transfer in some way (e.g., able to partially support weight)
  • Can perform basic daily care, such as feeding yourself and personal hygiene, with minimal assistance
There will be additional eligibility criteria that will be assessed and discussed with you by the study team at the time of screening.

How to participate:

If you are interested in participation and would like to learn more about the study, please contact:

Michele Sapoff
(212) 994-4569
msapoff@clinilabs.com

Additional information can be found on the clinicaltrials.gov website (NCT05579691)
https://clinicaltrials.gov/ct2/show/NCT05579691

On Thursday, September. 22, 2022, FARA hosted a webinar with Dr. Carole Ben-Maimon, CEO of Larimar Therapeutics, to update the community on the status of CTI-1601. The recorded webinar can be found here: https://youtu.be/jg4Gocp0qPU.

SHARE
 
Privacy Policy      Service Terms      Contact      Charity Navigator